Tumor-associated antigen presented via major histocompatibility complex class I and II pathway

Tumor-associated antigens presented via major histocompatibility complex (MHC) class I and II pathways refer to intracellular or extracellular peptide fragments derived from tumor-specific proteins (including mutated proteins, post-translationally modified proteins, or proteins overexpressed in tumor cells) that are processed and loaded onto MHC class I or II molecules for surface display on tumor cells or antigen-presenting cells[1][2]. MHC class I molecules generally present antigens to CD8+ cytotoxic T lymphocytes, enabling direct killing of tumor cells, while MHC class II molecules present antigens to CD4+ helper T cells, which coordinate the antitumor immune response[1][3]. Examples include peptides from proteins such as MART-1 in melanoma and phosphoepitopes associated with abnormal signaling[1]. The efficacy of immunotherapies relies on efficient presentation of these antigens, but diverse mechanisms can lead to their loss or alteration on tumors, enabling immune evasion[2][3]. While "tumor-associated antigens presented via MHC I and II pathways" captures relevant biology, it is not a specific molecule or protein—rather, it is a functional category of antigens defined by their presentation context, making this entry too generic or non-canonical for structured target databases.

Other names

Tumor antigen presented via MHC ITumor antigen presented via MHC IIMHC-restricted tumor antigenTumor-specific antigen presented via HLA

Peptide presentation to T cells (CD8+ via MHC I, CD4+ via MHC II), leading to immune-mediated tumor cell killing[1][2][3]